Boris Greber | Chief Scientific Officer
RheinCell Therapeutics

Boris Greber, Chief Scientific Officer, RheinCell Therapeutics

2018-        Chief Scientific Officer and Head of Production
        RheinCell Therapeutics GmbH, Langenfeld, Germany
2012-2017    Independent Research Group Leader 
Max Planck Institute for Molecular Biomedicine, Münster, and Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany
2008-2012    Senior Research Scientist / Project Group Leader
Max Planck Institute for Molecular Biomedicine, Münster, Germany (with Hans Schöler)
2005-2008    Postdoc 
        Max Planck Institute for Molecular Genetics, Berlin, Germany (with James             Adjaye)
2001-2005    Ph.D. studies 
Max Planck Institute for Molecular Genetics, Berlin, Germany (with Heinz Himmelbauer and Hans Lehrach)
1996-2000    B.Sc./M.Sc. Biochemistry studies 
University of Potsdam, Germany, and John Innes Centre, Norwich, UK

Appearances:



Conference Day 2 - Wednesday 1st April 2020 @ 14:20

HLA-homozygous (HLAh) induced pluripotent stem (iPS) cells as universal source for ATMP development

Conference Day 2 - Wednesday 1st April 2020 @ 15:40

TBC: Panel discussion: Ensuring safe clinical development of next generation therapeutics

last published: 06/Dec/19 09:35 GMT

back to speakers